PHAXIAM Therapeutics S.A. (PHXM) Stock
PHXM is no longer traded. PHAXIAM Therapeutics was delisted from the Nasdaq in March 2024.
Prices on this page are historical; the last trade was March 8, 2024 at $3.10.
PHAXIAM Therapeutics stock price history
PHXM final trading statistics
- Final close
- $3.10
- Final trading day
- Mar 8, 2024
- Market cap at delisting
- $18.83M
- Shares outstanding
- 6.07M
- Final 52-week range
- $0.39 – $6.39
- Avg. volume (final 3 mo.)
- 1,841
- All-time high (split-adj.)
- $330.50 · Oct 2017
- All-time low (split-adj.)
- $2.50 · Mar 2024
- Return since IPO
- -99.1%
- Beta
- 1.96
- Book value / share
- $6.03
- Price / book
- 0.51
PHAXIAM Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | — | -$23.5M | — |
| FY2022 | $0.00 | -$227.0K | -$0.05 |
| FY2021 | $0.00 | -$53.8M | -$2.46 |
| FY2020 | $0.00 | -$73.3M | -$4.76 |
| FY2019 | $5.28M | -$62.7M | -$3.84 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
PHAXIAM Therapeutics stock FAQ
What happened to PHAXIAM Therapeutics stock?
PHAXIAM Therapeutics stock was delisted from the Nasdaq. Its final close was $3.10 on March 8, 2024.
Is PHXM stock still trading?
No. PHXM was delisted from the Nasdaq in March 2024 and no longer trades on a U.S. exchange.
What was the last price of PHXM stock?
PHXM closed at $3.10 on its final trading day, March 8, 2024, for a market value of about $18.83M.
What were PHAXIAM Therapeutics's revenue and earnings in its last full fiscal year?
PHAXIAM Therapeutics reported revenue of — and net income of -$23.5M in fiscal 2023, its last full year as a public company.
When did PHAXIAM Therapeutics go public?
PHAXIAM Therapeutics S.A. stock began trading on June 29, 2023.